TLC-ART Program


Gao Y, Kraft JC, Yu D, Ho RJY.  (2018) Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy Eur J Pharm Biopharm PMID:  29678735

Perazzolo S, Shireman LM, Koehn J, McConnachie LA, Kraft JC, Shen DD, Ho RJY. (2018) Three HIV drugs, atazanavir, ritonavir and tenofovir co-formulated in drug-combination nanoparticles exhibit long-acting and lymphocyte targeting properties in non-human primates J Pharm Sci. PMID:  30121315

Simoni J, Beima-Sofie K, Mohamed ZH, Christodoulou J, Tapia K, Ho RJY, Collier AC. (2018) Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study among U.S. Providers, Adults Living with HIV, and Parents of Youth Living with HIV (Resubmitted)

Koehn J, Iwamoto JF, Kraft JC, McConnachie LA, Collier AC, Ho RJY. (2018) Extended cell and plasma drug levels after one dose of a 3-in-1 nanosuspension containing lopinavir, efavirenz, and tenofovir in non-human primates. AIDS. PMID:  30102655

 Mcconnachie LA, Kinman LM, Koehn J, Kraft JC, Lane S, Lee W, Collier AC, Ho RJY.  (2018) Long-Acting Profile of Four Drugs in One anti-HIV Nanosuspension in Non-Human Primates for Five Weeks Following a Single Subcutaneous Injection.  J Pharm Sci. PMID:  29548975.

Kraft JC, Treuting PM, Ho RJ. (2018) Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution, and retention and enable detailed mapping of lymph vessels, nodes, and abnormalities. J Drug Target. PMID: 29388438.

Kraft JC, McConnachie LA, Koehn J, Kinman L, Collier AC, Collins C, Shen DD, Ho RJY. (2018) Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation. Journal of Controlled Release. PMID: 29432823.

Mu Q, Yu J, McConnachie LA, Kraft JC, Gao Y, Gulati GK, Ho RJY. (2018) Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook. J Drug Target. PMID: 29285948.

Ho RJ, Yu J, Li B, Kraft JC, Freeling JP, Koehn J, Shao J (2015) Systems Approach to targeted and long-acting HIV/AIDS therapy. Drug Deliv Transl Res. PMID: 26315144.

Shao J, Kraft JC, Li B, Yu J, Freeling J, Koehn J, Ho RJ (2016) Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS. Nanomedicine (Lond). PMID: 26892323.

Partridge SC, Kurland BF, Liu CL, Ho RJ, Ruddell A (2016) Tumor-induced lymph node alterations detected by MRI lymphography using gadolinium nanoparticles. Sci Rep. PMID: 26497382, PMCID: PMC4620490.

Koehn J, Ding Y, Freeling J, Duan J, Ho RJ. A simple, efficient, and sensitive method for simultaneous detection of anti-HIV drugs atazanavir, ritonavir, and tenofovir by use of liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother. 2015 Nov;59(11):6682-8. doi: 10.1128/AAC.00869-15. Epub 2015 Jul 27. PubMed PMID: 26248367; PubMed Central PMCID: PMC4604393.

Volkin DB, Hershenson S, Ho RJ, Uchiyama S, Winter G, Carpenter JF. Two decades of publishing excellence in pharmaceutical biotechnology. J Pharm Sci. 2015 Feb;104(2):290-300. doi: 10.1002/jps.24285. Epub 2014 Dec 1. PubMed PMID: 25448882; PubMed Central PMCID: PMC4826475.

Freeling JP, Ho RJ. Antiretroviral nanoparticles: the future is now: authors’ response to editorial comments. AIDS. 2015 Apr 24;29(7):863-4. doi: 10.1097/QAD.0000000000000600. PubMed PMID: 25985411; PubMed Central PMCID: PMC4827420.

Zhang YJ, Zhan X, Wang L, Ho RJ, Sasaki T. pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model. J Pharm Sci. 2015 May;104(5):1815-24. doi: 10.1002/jps.24407. Epub 2015 Mar 9. PubMed PMID: 25753991; PubMed Central PMCID: PMC4830345.

Shao J, Kraft JC, Li B, Yu J, Freeling J, Koehn J, Ho RJ. Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS. Nanomedicine (Lond). 2016;11(5):545-64. doi: 10.2217/nnm.16.1. Epub 2016 Feb 19. PubMed PMID: 26892323; PubMed Central PMCID: PMC4910949.

Ho RJ, Chien J. Trends in translational medicine and drug targeting and delivery: new insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancers. J Pharm Sci. 2014 Jan;103(1):71-7. doi: 10.1002/jps.23761. Epub 2013 Nov 1. PubMed PMID: 24186148; PubMed Central PMCID: PMC4634700.

Koehn J, Ho RJ. Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs Lopinavir, Ritonavir, and Tenofovir in plasma. Antimicrob Agents Chemother. 2014 May;58(5):2675-80. doi: 10.1128/AAC.02748-13. Epub 2014 Feb 24. PubMed PMID: 24566184; PubMed Central PMCID: PMC3993260.

Ho RJ, Huang L. Interactions of antigen-sensitized liposomes with immobilized antibody: a homogeneous solid-phase immunoliposome assay. J Immunol. 1985 Jun;134(6):4035-40. PubMed PMID: 3886794.

Xiang L, Chi T, Tang Q, Yang X, Ou M, Chen X, Yu X, Chen J, Ho RJ, Shao J, Jia L. A pentacyclic triterpene natural product, ursolic acid and its prodrug US597 inhibit targets within cell adhesion pathway and prevent cancer metastasis. Oncotarget. 2015 Apr 20;6(11):9295-312. PubMed PMID: 25823660; PubMed Central PMCID: PMC4496218.

Freeling J, Ho RJ, Anti-HIV drug particles may overcome lymphatic drug insufficiency and associated HIV persistence. PNAS 2014 June 2; 111(25) E2512-E2513. Doi:10.1073/pnas.1406554111

Freeling J, Koehn J, Cuiling S, Jianguo S, Ho RJ. Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood. AIDS. 2014 November 13;28(17) 2625-2627. doi:10.1097/QAD.0000000000000421

Freeling J, Koehn J, Shu C, Sun J, Ho RJ. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. 2015; 31(1) 107-113. Doi: 10.1089/aid.2014.0210